The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis
Albert DeFelice(United States Food and Drug Administration), Raymond J. Lipicky, Stephen P. Glasser(University of Alabama at Birmingham), Morris Gordon(University of Lancashire), John Girton, James Hung(Zimmer Biomet (United States)), B Stertz, James Willard(United States Food and Drug Administration), Abraham Karkowsky(United States Food and Drug Administration), John Lawrence(Zimmer Biomet (United States)), Douglas C. Throckmorton(United States Food and Drug Administration), Shari Targum(Center for Drug Evaluation and Research)
Cited by 23
Related Papers
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
|Circulation|2018|712
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
|Circulation|2014|702
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
|Journal of the American College of Cardiology|2014|596
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406